ONKOLOGIE / Onkologie. 2023;17(3):164-168 / www.onkologiecs.cz 168 HLAVNÍ TÉMA ZACHOVÁNÍ FERTILITY U MLADÝCH PACIENTEK S KARCINOMEM PRSU VČETNĚ NOSIČEK MUTACÍ V GENECH BRCA1, BRCA2 ritní informovat včas ženy o možnostech, jak plodnost a/nebo funkci vaječníků zachovat. Problematika onkofertility vyžaduje úzkou spolupráci mezi onkology a specialisty pracovišť reprodukční medicíny. Zachování fertility by mělo patřit mezi základní předpoklady komplexní a kvalitní multidisciplinární péče o premenopauzální pacientku s karcinomem prsu. Možnost mít vlastní děti je obrovská motivace a naděje pro mladé ženy, které se ocitly v těžké životní situaci vzhledem k nečekané diagnóze karcinomu prsu. LITERATURA 1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi: 10.3322/caac.21708. 2. Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 5th international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022;33(11):10971118 S0923753422018580. doi: 10.1016/j.annonc.2022.07. 007. 3. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308-3314. doi: 10.1200/JCO.2015.65.8013. 4. Lambertini M, Goldrat O, Clatot F, et al. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol. 2017;29(4):243252. doi: 10.1097/CCO. 0000000000000380. 5. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386-405. doi: 10.1093/jnci/ djr541. 6. Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and posttreatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1664-1678. doi: 10.1016/j.annonc.2020. 09.006. 7. Razeti MG, Spinaci S, Spagnolo F, et al. How I perform fertility preservation in breast cancer patients. ESMO Open. 2021;6(3). doi: 10. 1016/j.esmoop.2021.100112. 8. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151-1156. 9. Lambertini M, Fontana V, Massarotti C, et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast. 2018;41:51-56. doi: 10.1016/j. breast.2018.06.012. 10. Blondeaux E, Massarotti C, Fontana V, et al. The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and/or fertility preservation strategies in premenopausal women with early breast cancer. Front Oncol. 2021;11. doi: 10.3389/fonc.2021.690320. 11. McCarter K, Stewart J, Gordhandas S, et al. The use of fertility preservation services for cancer patients: a single institution experience. F&S Reports. 2022;3(4):349-354 S2666334122000800. doi: 10.1016/j.xfre.2022.08.001. 12. Duraes M, Rathat G, Bringer-Deutsch S, et al. Fertility preservation in patients of childbearing age treated for breast cancer: A nationwide cohort study. Breast. 2022;64:121-126. doi: 10.1016/j.breast.2022.05.006. 13. Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39(29):3293–3305. doi: 10.1200/JCO.21.00535 14. Anderson RA, Amant F, et al. The ESHRE Guideline Group on Female Fertility Preservation ESHRE guideline: female fertility preservation†. Hum Reprod Open. 2020;2020(4): hoaa052. doi: 10.1093/European/hoaa052 15. Huiart L, Bouhnik AD, Rey D, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48(13):1939-1946. doi: 10.1016/j.ejca.2012.03.004 16. Pistilli B, Paci A, Ferreira AR, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38(24):2762-2772. doi: 10.1200/ JCO.19.01758. 17. Llarena NC, Estevez SL, Tucker SL, et al. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107(10): djv202. doi: 10.1093/jnci/djv202 18. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537. doi: 10.1007/ s10549-010-1132-4. 19. Lambertini M, Di Maio M, Pagani O, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41-49. doi: 10.1016/j. breast. 2018.08.099. 20. Khan SZ, Arecco L, Villarreal-Garza C, et al. Knowledge, practice, and attitudes of physicians in low – and middle-income countries on fertility and pregnancy-related issues in young women with breast cancer. JCO Glob Oncol. 2022;8: e2100153. doi: 10.1200/GO.21.00153. 21. Kassem L, Mellas N, Tolba M, et al. Awareness and practices of Arab oncologists towards oncofertility in young women with cancer. ecancer. 2022;16:1388. doi: 10.3332/ecancer.2022.1388. 22. Ayuandari S, Khasanah N, Riyanti I, et al. Current awareness and attitude toward fertility preservation in Indonesia: a nationwide survey among health-care providers. J Hum Reprod Sci. 2021;14(1):81. doi: 10.4103/jhrs.jhrs_239_20. 23. García A, Candás G, Bemi A, et al. Survey of professionals on breast cancer, fertility preservation and pregnancy in Argentina. ecancer. 2021;15:1183. doi: 10.3332/ ecancer.2021.1183. 24. Anderson RA, Cameron D, Clatot F, et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update. 2022;28(3):417-434. doi: 10. 1093/humupd/dmac004. 25. Lambertini M, Marrocco C, Spinaci S, et al. Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue. Eur J Clin Invest. 2022;52(7):e13779. doi: 10.1111/eci.13779. 26. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment- -related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791-798. doi: 10.1002/cncr.24835. 27. Lambertini M, Campbell C, Bines J, et al. Adjuvant anti- -HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86-94. doi: 10.1093/jnci/djy094. 28. Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589-596. doi: 10.1007/ s10549-015-3426-z. 29. Ruddy KJ, Zheng Y, Tayob N, et al. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021;189(1):103-110. doi: 10.1007/s10549-021-06267-8. 30. Vukovic´ P, Peccatori FA, Massarotti C, et al. Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Crit Rev Oncol Hematol. 2021;157. doi: 10.1016/j.critrevonc.2020. 103201. 31. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA doublestrand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172). doi: 10.1126/ scitranslmed.3004925. 32. van Tilborg TC, Broekmans FJ, Pijpe A, et al. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? Menopause. 2016;23(8):903-910. doi: 10. 1097/ GME.0000000000000633. 33. Johnson L, Sammel MD, Domchek S, et al. Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;107(5):1256-1265.e6. doi: 10.1016/j.fertnstert.2017.03.018. 34. Gunnala V, Fields J, Irani M, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):363-371. doi: 10.1016/j. fertnstert.2018.10.014. 35. Michaelson-Cohen R, Mor P, Srebnik N, et al. T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233-237. doi: 10.1097/ IGC.0000000000000058. 36. Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237-243. doi: 10.1093/annonc/mdx639. 37. Turan V, Lambertini M, Lee DY, et al. Association of Germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol. 2021;39(18):2016-2024. doi: 10.1200/JCO.20.02880. 38. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1 – or BRCA2 – mutated breast cancer. N Engl J Med. 2021;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. 39. Donnez J, Dolmans MM. Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657-1665. doi: 10.1056/ NEJMra1614676. 40. Lambertini M, Pescio MC, Viglietti G, et al. Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Rev Qual Life Cancer Care. 2017;2(1):47-59. doi: 10.1080/23809000.2017.1270760. 41. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96(2):277-285. doi: 10.1016/j. fertnstert.2011.06.030. 42. von Wolff M, Bruckner T, Strowitzki T, et al. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases – an analysis of 992 stimulations. J Assist Reprod Genet. 2018;35(9):1713-1719. doi: 10.1007/s10815-018-1227-0 43. Lawrenz B, Jauckus J, Kupka M, et al. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril. 2010;94(7):2871-2873. doi: 10.1016/j.fertnstert.2010.06.054. 44. Cobo A, García-Velasco J, Domingo J, et al. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222-2231. doi: 10.1093/humrep/dey321. 45. Diaz-Garcia C, Domingo J, Garcia-Velasco JA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478-485.e2. doi: 10.1016/j.fertnstert.2017.11.018. 46. Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424-2429. doi: 10.1200/ JCO.2014.59.3723. 47. Arecco L, Blondeaux E, Bruzzone M, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022;37(5):954-968. doi: 10.1093/humrep/deac035. Další literatura u autorky a na www.onkologiecs.cz
RkJQdWJsaXNoZXIy NDA4Mjc=